Tag:
ANA975
Latest Headlines
Latest Headlines
Novartis, Anadys abandon hep C drug
Anadys Pharmaceuticals and its development partner Novartis announced today that they will discontinue the development of ANA975, a Phase I compound for hepatitis C. Results from two 13-week
